An End to Heart Disease? Not Quite

THE NEW YORK TIMES | on Mon, Mar 20, 4:47 PM

It may seem obvious that lowering LDL cholesterol would inevitably reduce the risk of heart disease. But drugs can be unpredictable. They tend to have many effects. A drug that ameliorates one risk factor might have other effects that offset the benefit. On Friday, investigators reported the results of a highly anticipated trial of a PCSK9 inhibitor called evolocumab (brand name Repatha). This medication reduced LDL levels to an almost unfathomable 30 mg/dl from about 90 mg/dl on average, whi...

Read the full article

Semantic processing powered by OpenCalais

Use of the DailyMe service and DailyMe web site constitutes acceptance of the Company's Terms of Service and Privacy Policy.

© 2017 DailyMe, Inc. All rights reserved.